Difference Between Full-Year Consolidated Earnings Forecast and Actual Results
PHC Holdings Corporation
Healthcare Solutions, Diabetes Management
Lower profit in Healthcare Solutions, strong performance in Diabetes Management, cost controls, taxes arising from the repayment of capital by a subsidiary, and recognition of deferred tax liabilities associated with dividends paid by a subsidiary
Compared with the previous forecast, revenue increased by ¥1,303 million, operating profit increased by ¥2,688 million, profit before tax increased by ¥1,990 million, profit for the year decreased by ¥1,781 million, profit for the year attributable to owners of the parent decreased by ¥1,508 million, basic earnings per share decreased by ¥11.92, and adjusted EBITDA increased by ¥4,159 million. Income tax expense increased by approximately ¥3.8 billion.
Fiscal year ending March 2026 (1 April 2025 to 31 March 2026)
A difference arose between the full-year consolidated earnings forecast and actual results. No revision to the earnings forecast was stated. The Company plans to maintain its previously forecast year-end dividend of ¥21.
As business performance is exceeding the forecast, the Company plans to maintain its previously forecast year-end dividend of ¥21.
| Item | Details |
|---|---|
| Event name | Difference Between Full-Year Consolidated Earnings Forecast and Actual Results |
| Date of occurrence | 31 March 2026 (end date of the period covered by the actual results) |
| Date recognized / date notice received | 13 May 2026 (date the difference was disclosed) |
| Subject Entity | PHC Holdings Corporation |
| Target Locations / Products | Healthcare Solutions, Diabetes Management |
| Cause | Lower profit in Healthcare Solutions, strong performance in Diabetes Management, cost controls, taxes arising from the repayment of capital by a subsidiary, and recognition of deferred tax liabilities associated with dividends paid by a subsidiary |
| Amount of Impact on Business Performance | Compared with the previous forecast, revenue increased by ¥1,303 million, operating profit increased by ¥2,688 million, profit before tax increased by ¥1,990 million, profit for the year decreased by ¥1,781 million, profit for the year attributable to owners of the parent decreased by ¥1,508 million, basic earnings per share decreased by ¥11.92, and adjusted EBITDA increased by ¥4,159 million. Income tax expense increased by approximately ¥3.8 billion. |
| Accounting period in which recognized | Fiscal year ending March 2026 (1 April 2025 to 31 March 2026) |
| Impact on Earnings Forecast | A difference arose between the full-year consolidated earnings forecast and actual results. No revision to the earnings forecast was stated. The Company plans to maintain its previously forecast year-end dividend of ¥21. |
| Outlook | As business performance is exceeding the forecast, the Company plans to maintain its previously forecast year-end dividend of ¥21. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit exceeded the forecast because strong performance in Diabetes Management and cost controls offset lower profit in Healthcare Solutions. Income tax expense, however, increased by approximately ¥3.8 billion due to taxes arising from the repayment of capital by a subsidiary and recognition of deferred tax liabilities associated with dividends paid by a subsidiary.